Top

Published in:

01-05-2008 | Letter

Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?

Authors: Theodore Liakakos, Dimitrios H. Roukos

Published in: Surgical Endoscopy | Issue 5/2008

Excerpt

The safety and efficacy of laparoscopic gastrectomy has been demonstrated in phase II studies [1] and remain to be confirmed in large-scale phase III clinical trials. There are two potential advantages for performing laparoscopic gastrectomy rather than open gastrectomy: first, it improves quality of life (QOL) and, second, an increase in survival rates. Based on data from laparoscopic colorectal surgery, it is unlikely that laparoscopic gastrectomy may improve survival or cure rates for gastric cancer patients. What is the impact of laparoscopic approach on QOL? …

Lee JH, Kim YW, Ryu KW (2007) A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol. Aug 20; [Epub ahead of print]

Shehzad K, Mohiuddin K, Nizami S et al (2007) Current status of minimal access surgery for gastric cancer. Surg Oncol 16(2):85–98. Epub 2007 Jun 7PubMedCrossRef

Yasuda K, Shiraishi N, Etoh T, Shiromizu A, Inomata M, Kitano S (2007) Long-term quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer. Surg Endosc 21:2150–215PubMedCrossRef

Sakuramoto S, Sasako M, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810–1820PubMedCrossRef

Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20PubMedCrossRef

Roukos DH, Hottenrott C, Lorenz M, Koutsogiorgas Couchell S (1990) A critical-evaluation of effectivity of extended lymphadenectomy in patients with carcinoma of the stomach—an analysis of early results and long-term survival. J Cancer Res Clin 116(3):307–313CrossRef

Siewert JR, Bottcher K, Stein HJ, Roder JD (1998) Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228(4):449–461PubMedCrossRef

Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81(2):59–62PubMedCrossRef

Kappas AM, Fatouros M, Roukos DH (2004) Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 11(8):727–730PubMedCrossRef

10.

Roukos DH (2004) Early-stage gastric cancer: a highly treatable disease. Ann Surg Oncol Feb;11(2):127–129CrossRef

11.

Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125PubMedCrossRef

12.

Gervasoni JE, Sbayi S, Cady B (2007) Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol (in press) DOI: 10.1245/s10434-007-9360-5

13.

Roukos DH, Kappas AM (2005) Perspectives in the treatment of gastric cancer. Nat Clin Pract Oncol 2:98–107PubMedCrossRef

14.

Roukos DH, Lorenz M, Karakostas K, Paraschou P, Batsis C, Kappas AM (2001) Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study. Br J Cancer 84(12):1602–1609PubMedCrossRef

15.

Roukos DH (1998) Extended lymphadenectomy in gastric cancer: when, for whom and why. Ann R Coll Surg Engl 80(1):16–24PubMed

16.

Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7(4):253–255PubMedCrossRef

17.

Roukos DH (1999) Current advances and changes in treatment strategy may improve survival and quality of life in patients with potentially curable gastric cancer. Ann Surg Oncol 6(1):46–56PubMedCrossRef

18.

Roukos DH, Lorenz M, Encke A (1998) Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: a prospective long-term follow-up study. Surgery 123(5):573–578PubMedCrossRef

19.

Macdonald JS, Smalley SR, Benedetti J et al (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730PubMedCrossRef

20.

Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9(3):220–221PubMedCrossRef

21.

Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14(10):2691–2695PubMedCrossRef

22.

Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6(6):931–939PubMedCrossRef

23.

Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245(6):873–879PubMedCrossRef

24.

Chung DC, Yoon SS, Lauwers GY, Patel D (2007) Case records of the Massachusetts General Hospital. Case 22–2007. A woman with a family history of gastric and breast cancer. N Engl J Med 357(3):283–291PubMedCrossRef

25.

Roukos DH, Murray S, Briasoulis E (2007) Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6(3):308–312PubMedCrossRef

26.

Kim JJ, Song KY, Chin HM, Kim W, Jeon HM, Park CH, Park SM (2007) Totally laparoscopic gastrectomy with various types of intracorporeal anastomosis using laparoscopic linear staplers: preliminary experience. Surg Endosc Jun 26; [Epub ahead of print]

27.

Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590PubMedCrossRef

28.

Roukos DH, Kappas AM, Tsianos E (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Ann Surg Oncol 9(7):607–609PubMedCrossRef

29.

Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943PubMed

30.

Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15:21–33PubMedCrossRef

31.

Agnantis NJ, Paraskevaidis E, Roukos D (2004) Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11(12):1030–1034PubMedCrossRef

32.

Roukos DH (2007) Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:1555–1556PubMedCrossRef

33.

Roukos DH, Kappas AM, Agnantis NJ (2003) Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10(7):718–721PubMedCrossRef

34.

Fatouros M, Roukos DH, Arampatzis I, Sotiriadis A, Paraskevaidis E, Kappas AM (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745PubMedCrossRef

35.

Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–39PubMedCrossRef

36.

Liakakos T, Roukos DH (2008) More controversy than ever – challenges and promises towards personlized treatment of gastric cancer. Ann Surg Oncol 15(4):959–960PubMedCrossRef

37.

Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197PubMedCrossRef

38.

Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRef

Title: Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?
Authors: Theodore Liakakos
Dimitrios H. Roukos
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 5/2008
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-008-9890-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2008

Polyflex self-expanding, removable plastic stents: assessment of treatment efficacy and safety in a variety of benign and malignant conditions of the esophagus

Diagnostic yield, therapeutic impact, and complications of double-balloon enteroscopy in patients with small-bowel pathology

Patient-centered measures for achalasia

Alternative choices of total and partial thymectomy in video-assisted resection of noninvasive thymomas

NOTES: Where have we been and where are we going?

Day case laparoscopic rectopexy is feasible, safe, and cost effective for selected patients